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RNA interference-mediated c-MYC inhibition prevents cell
growth and decreases sensitivity to radio- and chemotherapy in
childhood medulloblastoma cells
Abstract
BACKGROUND: With current treatment strategies, nearly half of all medulloblastoma (MB) patients
die from progressive tumors. Accordingly, the identification of novel therapeutic strategies remains a
major goal. Deregulation of c-MYC is evident in numerous human cancers. In MB, over-expression of
c-MYC has been shown to cause anaplasia and correlate with unfavorable prognosis. METHODS: To
study the role of c-MYC in MB biology, we down-regulated c-MYC expression by using small
interfering RNA (siRNA) and investigated changes in cellular proliferation, cell cycle analysis,
apoptosis, telomere maintenance, and response to ionizing radiation (IR) and chemotherapeutics in a
representative panel of human MB cell lines expressing different levels of c-MYC (DAOY wild-type,
DAOY transfected with the empty vector, DAOY transfected with c-MYC, D341, and D425).
RESULTS: siRNA-mediated c-MYC down-regulation resulted in an inhibition of cellular proliferation
and clonogenic growth, inhibition of G1-S phase cell cycle progression, and a decrease in human
telomerase reverse transcriptase (hTERT) expression and telomerase activity. On the other hand,
down-regulation of c-MYC reduced apoptosis and decreased the sensitivity of human MB cells to IR,
cisplatin, and etoposide. This effect was more pronounced in DAOY cells expressing high levels of
c-MYC when compared with DAOY wild-type or DAOY cells transfected with the empty vector.
CONCLUSION: In human MB cells, in addition to its roles in growth and proliferation, c-MYC is also
a potent inducer of apoptosis. Therefore, targeting c-MYC might be of therapeutic benefit when used
sequentially with chemo- and radiotherapy rather than concomitantly.
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Abstract
Background: With current treatment strategies, nearly half of all medulloblastoma (MB) patients
die from progressive tumors. Accordingly, the identification of novel therapeutic strategies remains
a major goal. Deregulation of c-MYC is evident in numerous human cancers. In MB, over-
expression of c-MYC has been shown to cause anaplasia and correlate with unfavorable prognosis.
Methods: To study the role of c-MYC in MB biology, we down-regulated c-MYC expression by
using small interfering RNA (siRNA) and investigated changes in cellular proliferation, cell cycle
analysis, apoptosis, telomere maintenance, and response to ionizing radiation (IR) and
chemotherapeutics in a representative panel of human MB cell lines expressing different levels of
c-MYC (DAOY wild-type, DAOY transfected with the empty vector, DAOY transfected with c-
MYC, D341, and D425).
Results: siRNA-mediated c-MYC down-regulation resulted in an inhibition of cellular proliferation
and clonogenic growth, inhibition of G1-S phase cell cycle progression, and a decrease in human
telomerase reverse transcriptase (hTERT) expression and telomerase activity. On the other hand,
down-regulation of c-MYC reduced apoptosis and decreased the sensitivity of human MB cells to
IR, cisplatin, and etoposide. This effect was more pronounced in DAOY cells expressing high levels
of c-MYC when compared with DAOY wild-type or DAOY cells transfected with the empty
vector.
Conclusion: In human MB cells, in addition to its roles in growth and proliferation, c-MYC is also
a potent inducer of apoptosis. Therefore, targeting c-MYC might be of therapeutic benefit when
used sequentially with chemo- and radiotherapy rather than concomitantly.
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Medulloblastomas (MB) are the most common malignant
pediatric neoplasms of the central nervous system. MB
constitute 20% of all pediatric brain tumors [1] and are
characterized by their aggressive clinical behavior and a
high risk of leptomeningeal dissemination. With current
treatment strategies, nearly half of all patients eventually
die from progressive tumors. Accordingly, the identifica-
tion of novel therapeutic strategies remains a major goal.
The c-MYC proto-oncogene encodes a nuclear phospho-
protein involved in the transcription of genes central to
regulating the cell cycle [2-4], proliferation [5,6], apopto-
sis [7-9], telomere maintenance [10,11], angiogenesis
[12], and differentiation [13]. The c-MYC oncoprotein
plays a pivotal role as a regulator of tumorigenesis in
numerous human cancers of diverse origin [14-17].
Deregulated expression of c-MYC is often associated with
aggressive, poorly differentiated tumors [4]. Deregulation
of c-MYC expression is evident in MB with c-MYC gene
amplification or aberrant signal transduction of wingless
(WNT) signaling pathway [18]. In MB, high c-MYC mRNA
expression and c-MYC gene amplification have been
described as indicators of poor prognosis [19-22]. Fur-
thermore, two studies have demonstrated that high c-
MYC mRNA expression is associated with tumor anapla-
sia [23,24].
Developing therapeutic approaches to inhibit c-MYC
would have an enormous impact on the treatment of a
wide range of human cancers [25-27]. Many strategies are
currently under development to target c-MYC in tumor
cells, including inhibitors that block c-MYC expression,
such as antisense oligonucleotides and small interfering
RNA (siRNA) [28]. One aspect to be considered by evalu-
ating the potential of c-MYC as a novel therapeutic target
in MB, is its impact on cellular sensitivity to radio- and
chemotherapy. In the present study, siRNA-mediated c-
MYC inhibition was used to study the biological role of c-
MYC in a representative panel of human MB cells express-
ing different levels of c-MYC.
Methods
Human MB cell lines
DAOY (wild-type), DAOY V11 (empty vector-trans-
fected), and DAOY M2 (c-MYC-transfected) human MB
cells have been described previously [24]. D341 and D425
human MB cells were the kind gift of Dr Henry Friedman,
Duke University, Durham, NC, USA. DAOY, D341, and
D425 MB cell lines are derived from three different MB
obtained at craniotomy of patients aged 3–5 years
[21,29,30]. All MB cells were cultured in Richter's zinc
option medium (Invitrogen; Basel, Switzerland) supple-
mented with 10% fetal bovine serum. Non-essential
amino acids were added to the medium of D341 and
D425 cells to a final concentration of 1%, and G418 was
added to the medium of DAOY V11 and DAOY M2 to a
final concentration of 500 μg/ml. All cell cultures were
maintained at 37°C in a humidified atmosphere with 5%
CO2.
Down-regulation of c-MYC
The Silencer c-MYC validated siRNA targeting the 3'-
untranslated region of the human c-MYC mRNA sequence
[31,32], referred to here as c-MYC siRNA, and Silencer
scrambled c-MYC negative control siRNA, referred to here
as control siRNA, having no significant homology to any
known gene sequences from mouse, rat, or human, were
purchased from Ambion, and used according to the man-
ufacturer's instructions [33]. In brief, small interfering
RNAs (siRNAs) for c-MYC and scrambled control siRNA
were transfected at a final concentration of 30–60 nM
with siPORT amine (Ambion) in the case of DAOY MB
cells and with siPORT NeoFX (Ambion) in the case of
D341 and D425 MB cells as described before [34,35].
Comparable with other reports we found reproducible
inhibition of RNA and protein expression at 48–72 h post
transfection [34,35].
Real-time quantitative polymerase chain reaction
Total RNA isolation, reverse transcription reactions, and
RT-PCR were performed as described previously [36].
Kinetic real-time PCR quantification of target genes was
performed using the ABI Prism 7700 Sequence Detection
System (Applied Biosystems; Rotkreuz, Switzerland), as
described previously [36]. Primers and probes for c-MYC
(assay ID: Hs00153408_m1) and the endogenous control
18S rRNA (assay ID: Hs99999901_s1) were purchased
from Applied Biosystems (Rotkreuz, Switzerland). Prim-
ers and probes for hTERT were purchased from
Microsynth (Balgach, Switzerland): forward primer, 5'-
TGACACCTCACCTCACCCAC-3', reverse primer, 5'-
CACTGTCTTCCGCAAGTTCAC-3', probe, 5'-ACCCT-
GGTCCGAGGTGTGTCCCTGAG-3'. Experiments were
performed in triplicate for each data point. Relative
mRNA expression of target genes was calculated by using
the comparative CT method [37].
Western blot analysis
The expression of c-MYC, cyclin-dependent kinase (CDK)
inhibitor p21 (waf1/Cip1), caspase-9 and β-actin protein was
assessed by Western blot analysis. In brief, human MB
cells transfected with siRNAs for 72 h or treated with
chemotherapy for 72 h after 48 h of transfection with siR-
NAs, were lysed with lysis buffer (1 ml/107 cells, 50 mM
Tris-HCl buffer [pH 8.0], 150 mM NaCl, 1% Nonidet P40,
0.1% sodium deoxycholate, 0.1% sodium dodecylsulfate,
1 mM EDTA, and 1 mM EGTA) containing protease inhib-
itors (Complete, Roche; Basel, Switzerland) and incu-
bated on ice for 30 min. After measuring the proteinPage 2 of 14
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USA), 12 μg total protein lysates were separated by 10%
SDS-polyacrylamide gels and the gels were subjected to
immunoblotting. Nonspecific binding sites were blocked
by 3 h incubation in TBST (10 mM Tris [pH 8.0], 150 mM
NaCl, 0.05% Tween-20) supplemented with 5% non-fat
dry milk. Membranes were incubated overnight at 4°C
with a 1:2000 dilution of rabbit polyclonal anti-c-MYC
antibody (Santa Cruz Biotechnology; Heidelberg, Ger-
many), with a 1:1000 dilution of mouse monoclonal anti-
p21 (waf1/Cip1) antibody (Upstate), and with a 1:1000 dilu-
tion of rabbit polyclonal antibody specific for cleaved cas-
pase-9 (Cell signaling).
Membranes were then washed three times at room tem-
perature in TBST for 30 min each time, and bound Ig was
detected using anti-isotype monoclonal secondary anti-
body coupled to horseradish peroxidase (Santa Cruz Bio-
technology; Heidelberg, Germany). The signal was
visualized by enhanced chemiluminescence ECL (Amer-
sham Biosciences; Dübendorf, Switzerland) and autoradi-
ography. Next, immunoblotting with a 1:5000 dilution of
a mouse monoclonal primary β-actin antibody (Sigma;
Basel, Switzerland) was performed to verify the protein
loading. For densitometry, the zymographic profiles of
the gels were scanned. Relative band intensities were
determined using Quantity One analysis software (Bio-
Rad).
c-MYC transcription factor binding activation assay
The binding activation of c-MYC was measured using the
Mercury TransFactor assay (BD Clontech, Basel, Switzer-
land), an enzyme-linked immunosorbent assay (ELISA)-
based assay, according to the manufacturer's instructions,
as previously described [36].
Cell proliferation
Following transfection with siRNAs, a colorimetric 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) assay
(Promega; Wallisellen, Switzerland) was used to quanti-
tate cell viability of human MB cells, as previously
described [36]. Each experiment was performed in tripli-
cate. The absorbance values of each well were measured
with a microplate spectrophotometer (Molecular Devices;
Sunnyvale, CA) at 490 nm. All proliferation assays were
repeated as independent experiments at least twice.
Clonogenic survival assay
A clonogenic survival assay was performed using cells
transfected with siRNAs for 48 h, as described previously
[38]. The number of single cells seeded was adjusted to
obtain around 100 colonies per cell culture dish [39].
Cells were maintained at 37°C in a humidified atmos-
phere containing 5% CO2 and allowed to grow for 9
(DAOY wt, V11, M2), 14 (D341), or 12 (D425) days
respectively, before fixation in methanol/acetic acid
(75%:25%) and staining with Giemsa. Only colonies with
more than 50 cells were counted. All clonogenic assays
were repeated as independent experiments at least twice.
Cell cycle analysis
Cells transfected with siRNAs were harvested after 48 h by
trypsinization, washed with PBS 1×, and fixed with 1 ml
of 70% ethanol [38]. After washing twice in PBS, the cells
were stained with a solution containing 50 μg/ml propid-
ium iodide (Becton-Dickinson; Allschwil, Switzerland)
and 100 U/ml RNase A (Qiagen; Hombrechtikon, Swit-
zerland) in PBS for 30 min at room temperature. The per-
centage of cells in the different phases of the cell cycle was
determined by evaluating DNA content according to
methods previously described [36]. A total of 30'000
events per sample were acquired. Flow cytometric analysis
was performed on a FACSCalibur flow cytometer (BD Bio-
sciences; Allschwil, Switzerland) with CELLQuest soft-
ware (BD Biosciences). The percentages of cell cycle
distribution were calculated on linear PI histograms using
the mathematical software ModFit LT 2.0 (Verity Software
House; Topsham, ME)
Telomerase activity
Telomerase activity in MB cell lines was measured using
the Telomerase PCR ELISA kit (Roche Diagnostics;
Rotkreuz, Switzerland) as previously described [40]. For
this procedure, 106 cells were lysed and homogenized in
200 μl CHAPS buffer. After 30 min incubation on ice, the
lysates were centrifuged at 16,000 g for 30 min at 4°C.
Protein concentration was measured using the BCA
method (Pierce; Rockford, USA). For the elongation step,
2 μl of cell extract (2 μg protein/μl) were incubated in 50
μl reaction mixture at 25°C for 30 min to allow the telom-
erase to add telomeric repeats (TTAGGG) to the end of the
biotin-labeled synthetic P1-TS primer. The products
extended by telomerase were then amplified by PCR in the
presence of the biotin-labeled P1-TS primer and another
primer, P2. Amplification products from the PCR were
next immobilized in the well of a StreptAvidin-coated
microplate and hybridized to a digoxigenin (DIG)-
labeled probe specific for the telomeric repeat sequence.
Finally, the DIG-labeled hybrids were visualized with a
peroxidase-conjugated anti-DIG antibody and a colori-
metric peroxidase substrate and quantified photometri-
cally. In order to visualize the typical 6-nucleotide-ladder
resulting from the TRAP assay, the amplification products
from the PCR were separated by 12.5% polyacrylamide
gel electrophoresis (PAGE), blotted onto a positively
charged membrane, and incubated with a StreptAvidin
alkaline phosphatase conjugate. The blotted products
were visualized by enhanced chemiluminescence (BiotinPage 3 of 14
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Rotkreuz, Switzerland) and autoradiography.
Apoptosis assay
Cell lysates were obtained from exponentially growing
MB cells transfected with siRNAs for 72 h and from MB
cells treated with etoposide and cisplatin for 72 h after 48
h of transfection with siRNAs. A photometric enzyme
immunoassay (Cell Death Detection ELISA; Roche Diag-
nostics, Basel, Switzerland) was used for the quantitative
determination of cytoplasmic histone-associated DNA
fragments, as described previously [36]. In brief, after the
different treatment schedules, cells were counted, and cell
lysates of equal number of cells (5 × 104 cells/ml) were
placed in a StreptAvidin-coated microtiter plate. A mixture
of biotin-labeled monoclonal histone antibody and per-
oxidase-conjugated monoclonal DNA antibody was then
added, followed by incubation for 2 h. After washing to
remove unbound antibodies, the amount of mono- and
oligonucleosomes was measured at 405 nm (reference
wavelength 490 nm).
Chemo- and radio-sensitivity assays
After 48 h of transfection with c-MYC siRNA or control
siRNA, appropriate numbers of exponentially growing
MB cells were seeded in 96-well plates. Cells were treated
for 72 h with various concentrations of etoposide and cis-
platin or were irradiated with 4 Gy and 10 Gy, using a
Pantak Therapax 300 kV X-ray unit at 0.7 Gy/min. Dosim-
etry was controlled with a Vigilant dosimeter. Cell viabil-
ity of human MB cells was quantified using the MTS assay
72 h after adding the chemotherapeutic substances and
irradiation, respectively.
Statistical analysis
All data are expressed as mean ± SD. Student's t-test was
used to test statistical significance. P < 0.05 was consid-
ered to be significant. GraphPad Prism 4 (GraphPad Soft-
ware, San Diego, California) software was used to
calculate IC50 values and their 95% confidence intervals
and to statistically compare the fitted midpoints (log IC50)
of the two curves.
Results
Targeting c-MYC by siRNA in MB cells
To establish an efficient method of specifically down-reg-
ulating c-MYC expression in MB, we used a siRNA
approach. Transfection of human MB cells with siRNA
directed against c-MYC resulted in a pronounced down-
regulation of c-MYC mRNA expression to 21% in DAOY
wt (p < 0.001), 22% in DAOY V11 (p < 0.001), 6% in
DAOY M2 (p < 0.001), 33% in D341 (p < 0.001), and
65% in D425 (p = 0.017) compared with negative control
siRNA-transfected cells, as determined by quantitative RT-
PCR at 48 h following transfection (Figure 1A). At the pro-
tein level, transfection of human MB cells with c-MYC
siRNA resulted in a significant down-regulation of c-MYC
protein expression compared with negative control
siRNA-transfected cells as determined by Western blotting
72 h post transfection in all MB cell lines tested (Figure
1B). Transfection of human MB cells with c-MYC siRNA
resulted in a significant reduction of c-MYC binding acti-
vation to 10% in DAOY wt (p = 0.015), 28% in DAOY
V11 (p = 0.009), 21% in DAOY M2 (p = 0.008), 74% in
D341 (p = 0.05), and 63% in D425 (p = 0.03), compared
with MB cells transfected with negative control siRNA at
72 h following transfection (Figure 1C).
siRNA-mediated c-MYC down-regulation reduces cellular 
proliferation, inhibits clonogenic growth, induces G1 cell 
cycle arrest and CDK inhibitor p21(waf1/Cip1) expression in 
MB cells
To test whether siRNA-mediated reduction of c-MYC
alters cellular proliferation of human MB cells, we
assessed cell viability at 0, 2, 4, and 6 days following c-
MYC siRNA or control siRNA transfection. When com-
pared with control siRNA-transfected cells, growth was
lower in c-MYC siRNA-transfected MB cell lines (Figure
2A). This effect was independent of basal c-MYC expres-
sion. We then determined clonogenic survival using MB
cells transfected with control or c-MYC siRNA. After 48 h
of exposure to either c-MYC siRNA or to control siRNA,
the siRNA was removed, and clonogenic survival was
determined. When compared with control siRNA-trans-
fected cells, the clonogenic survival of c-MYC siRNA-trans-
fected cells was significantly reduced, as observed by
decreased number of large colonies (colonies with more
than 50 cells), to 67% in DAOY wt (p = 0.011), 78% in
DAOY V11 (p = 0.026), 26% in DAOY M2 (p = 0.038),
52% in D341 (p = 0.003), and 59% in D425 (p = 0.001)
human MB cells (Figure 2B). We then examined whether
alterations in the cell cycle underlie the c-MYC siRNA-
mediated effect on proliferation of MB cells. Flow cyto-
metric analysis of cells transfected with c-MYC siRNA for
48 h showed consistent changes in the cell cycle distribu-
tion compared with control siRNA-transfected cells. In all
cell lines tested, there was an increase in the number of
cells in the G0/G1 phase, which was significant in DAOY
wt (p = 0.028), DAOY V11 (p = 0.001), DAOY M2 (p =
0.033), and D341 (p = 0.006), but slightly below the sig-
nificance level in D425 (p = 0.062) (Figure 2C). In all MB
cells under study there was a decrease in the number of
cells in the S-phase, which was significant in DAOY V11
(p = 0.005) and DAOY M2 (p = 0.05), compared with
control siRNA-transfected cells. The observation that c-
MYC siRNA transfection resulted in an up-regulation of
CDK inhibitor p21 (waf1/Cip1) expression compared with
control siRNA-transfected cells to 153% in DAOY wt,
128% in DAOY V11, 239% in DAOY M2, 142% in D341,
and 198% in D425, as determined by Western blottingPage 4 of 14
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Knockdown of c-MYCFigure 1
Knockdown of c-MYC. c-MYC siRNA reduces c-MYC mRNA (A), protein (B) expression, and binding activity (C) as 
determined by quantitative RT-PCR, Western blot analysis, and by the ELISA-based TransAM-c-MYC binding activity assay 
(representative of two to three independent experiments). Values represent levels of c-MYC mRNA (n = 3; ± SD) (A) or pro-
tein (B) of control and c-MYC siRNA-transfected cells relative to control siRNA-transfected DAOY wt cells, which was set at 
100 (A, B). Data show the mean absorbance (n = 3; ± SD) (C). * Significantly different from control values, as determined by 
the Student's t-test (***: P < 0.001, **: P < 0.01,*: P < 0.05).
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BMC Cancer 2009, 9:10 http://www.biomedcentral.com/1471-2407/9/10and photometrical quantification (Figure 2D), was in
accordance with the G1 arrest induced by c-MYC down-
regulation. Taken together, these results demonstrate that
down-regulation of c-MYC inhibits tumor cell growth at
least partly by induction of cell cycle arrest
siRNA-mediated c-MYC down-regulation reduces 
apoptotic cell death in MB cells
To investigate whether the decrease in cellular growth
induced by c-MYC down-regulation was also caused by
increased levels of apoptosis, we determined apoptotic
cell death in siRNA-transfected MB cells (72 h). This anal-
ysis revealed that down-regulation of c-MYC resulted in a
reduction of apoptosis in all human MB cell lines tested
(Figure 3; DAOY wt: 79% (p = 0.12); DAOY V11: 76% (p
= 0.10); DAOY M2: 48% (p = 0.001); D341: 49% (p =
0.002), D425: 54% (p = 0.001)). This inhibitory effect on
apoptosis was more pronounced in human MB cell lines
expressing high levels of c-MYC. Cell cycle analysis of con-
trol and c-MYC siRNA-transfected cells revealed a decrease
in the proportion of cells in sub-G1 when exposed to c-
MYC siRNA to 74% in DAOY, to 50% in DAOY V11, to
47% in DAOY M2, to 48% in D341, and to 53% in D425
MB cells.
Knockdown of c-MYC reduces MB cell growth, induces G1 cell cycle arrest and CDK inhibitor p21 (waf1/Cip1)expressionFigure 2
Knockdown of c-MYC reduces MB cell growth, induces G1 cell cycle arrest and CDK inhibitor p21 (waf1/
Cip1)expression. c-MYC siRNA-transfected cells show reduced cell viability over time and inhibition of clonogenic survival 
compared with the control siRNA-transfected cells as determined by the MTS assay (A) and by a clonogenic survival assay (B). 
Cell cycle analysis of control and c-MYC siRNA-transfected cells harvested after 48 h by trypsinization, fixed in ethanol and 
stained with propidium iodide as described in Methods. A total number of 30'000 events per sample were counted. Results are 
presented as the mean percentages of cells in G1, S, and G2/M of two independent experiments (± standard deviation) (C). c-
MYC siRNA-mediated up-regulation of CDK inhibitor p21 (waf1/Cip1) expression compared with control siRNA-transfected cells 
as determined by Western blotting and photometrical quantification at 72 h post transfection. Values represent the percentage 
of p21 (waf1/Cip1)relative to control siRNA-transfected cells (D). * Indicates a significant difference compared to control values, 
as determined by the Student's t-test (***: P < 0.001, **: P < 0.01,*: P < 0.05).
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BMC Cancer 2009, 9:10 http://www.biomedcentral.com/1471-2407/9/10siRNA-mediated c-MYC down-regulation reduces hTERT 
mRNA expression and telomerase activity in MB cells
To investigate the effects of c-MYC down-regulation on
telomerase in MB cells, we determined hTERT mRNA
expression by using quantitative RT-PCR at 48 h following
transfection with c-MYC siRNA or control siRNA. We
found a significant reduction of hTERT mRNA expression
in c-MYC siRNA-transfected cells to 34% in DAOY wt,
54% in DAOY V11, 21% in DAOY M2, 15% in D341, and
35% in D425 compared with negative control siRNA-
transfected cells, as determined by real-time RT-PCR (Fig-
ure 4A). We then determined the effect of c-MYC down-
regulation on the enzymatic activity of telomerase and
performed a modified TRAP assay on cell lysates 72 h post
transfection. This analysis revealed that telomerase activ-
ity was inhibited in c-MYC siRNA-transfected DAOY wt,
DAOY V11, DAOY M2, and D341 MB cells (Figure 4B).
Telomerase activity was found to be reduced to 77% in
DAOY wt, 79% in DAOY V11, 63% in DAOY M2, and
30% in D341, compared with negative control siRNA-
transfected cells (Figure 4C). In D425 MB cells, which are
characterized by low TRAP activity [40], c-MYC inhibition
did not alter the telomerase activity (Figure 4B,C).
siRNA-mediated c-MYC down-regulation decreases radio-
sensitivity of MB cells
DAOY, D341, and D425 human MB cells transfected with
c-MYC or control siRNA were irradiated with 0, 4, and 10
Gy and cell viability was quantified after 72 h. D341 and
D425 were more sensitive to IR than DAOY cells harbor-
ing mutant p53 [41] (Figure 5). DAOY M2 cells engi-
neered to express higher c-MYC levels were more
susceptible to IR than DAOY wt or DAOY V11 (Figure 5).
Compared with control siRNA-transfected cells, c-MYC
c-MYC siRNA-mediates a reduction in apoptotic cell deathFigure 3
c-MYC siRNA-mediates a reduction in apoptotic cell death. Reduced apoptotic levels in cells transfected with c-MYC 
siRNA compared with control siRNA-transfected cells at 72 h post transfection. Values represent the mean absorbance of 
cytoplasmatic histone-associated DNA fragments (representative of two independent experiments, (n = 3; ± SD)). * Indicates a 
significant difference compared to control values, as determined by Student's t-test (***: P < 0.001, **: P < 0.01,*: P < 0.05).
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BMC Cancer 2009, 9:10 http://www.biomedcentral.com/1471-2407/9/10siRNA-transfected cells were more resistant to killing by IR
(Figure 5).
siRNA-mediated c-MYC down-regulation decreases 
chemo-sensitivity of MB cells
To investigate whether siRNA-mediated down-regulation
of c-MYC alters chemo-sensitivity of MB cells, we meas-
ured the cytotoxic response to etoposide and cisplatin. In
the case of cisplatin treatment, c-MYC siRNA transfection
resulted in a significant decrease in chemo-sensitivity in
DAOY M2 (p < 0.001), D425 (p = 0.003), and D341 (p =
0.013) (Figure 6A). However, no changes in chemo-sensi-
tivity were observed in DAOY wt and DAOY V11 human
MB cells (Figure 6A). In the case of etoposide treatment, c-
MYC siRNA transfection resulted in a significant decrease
in chemo-sensitivity in DAOY wt (p < 0.0001), DAOY V11
(p < 0.0001), DAOY M2 (p < 0.0001), and D341 (p <
0.001), and a minor decrease in D425 (p = 0.12) (Figure
6B).
siRNA-mediated c-MYC down-regulation attenuates the 
cellular apoptotic response of DAOY MB cells to 
chemotherapy that is associated with reduced caspase-9 
activity
To investigate whether the reduction of chemo-sensitivity
induced by c-MYC down-regulation, as measured by cell
viability (Figure 6), was caused by decreased levels of
apoptosis, we measured the apoptotic cell death in siRNA-
transfected (48 h) DAOY M2 cells – showing significant
difference in viability following c-MYC down-regulation
and treatment with cisplatin and etoposide – after treat-
ment with either cisplatin or etoposide for 72 h. DAOY
c-MYC siRNA-mediates inhibition of hTERT mRNA expression and telomerase activityFigure 4
c-MYC siRNA-mediates inhibition of hTERT mRNA expression and telomerase activity. Inhibition of hTERT 
mRNA expression (A) and telomerase activity (B, C) by c-MYC down-regulation as determined by quantitative RT-PCR (A), 
by the TRAP assay showing typical products of telomerase activity (6-nucleotide telomerase product ladder) with bands start-
ing from 50 bp and the internal control (IC) in a single band of 216 bp (B), and by the TeloTAGGG telomerase polymerase 
chain reaction (PCR) enzyme-linked immunosorbent assay (ELISA) kit (C). Values represent the percentage of hTERT mRNA 
(n = 3; ± SD) and mean absorbance (n = 3; ± SD) of control and c-MYC siRNA-transfected cells (A, C).
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BMC Cancer 2009, 9:10 http://www.biomedcentral.com/1471-2407/9/10V11 was included as a control. Following c-MYC down-
regulation, siRNA-transfected DAOY V11 cells were
equally sensitive to cisplatin in terms of viability and
induction of apoptosis (Figure 6A, 7A). In the case of
etoposide treatment, c-MYC siRNA-treated DAOY V11
cells showed reduced cellular sensitivity (Figure 6B) and
only a moderate induction of apoptosis compared to con-
trol siRNA-transfected cells (Figure 7B). Treatment of con-
trol siRNA-transfected DAOY M2 cells with cisplatin and
etoposide resulted in a dose-dependent increase of apop-
totic cell death when compared with c-MYC siRNA-trans-
fected DAOY M2 cells. Most of the chemotherapeutics,
including cisplatin and etoposide [42,43], induce apopto-
sis mainly through the mitochondrial pathway. Mito-
chondria-mediated apoptosis involves the cleavage of
pro-caspase-9 into the active caspase-9. Next, we exam-
ined processing of caspase-9 in DAOY M2 cells, trans-
fected with siRNAs for 48 h and treated for 72 h with
cisplatin and etoposide. More caspase-9 cleavage was
detected in control siRNA-transfected cells compared to c-
MYC siRNA-transfected DAOY M2 cells as determined by
Western blotting. This analysis suggests that down-regula-
tion of c-MYC inhibits the apoptotic response to chemo-
therapy that appears at least partly mediated by caspase-9.
Discussion
Whereas the impact of c-MYC gene amplification and c-
MYC mRNA over-expression on MB histology and prog-
nosis has been investigated intensively [19-24], the bio-
logical functions of c-MYC in MB cells remain largely
elusive. To our knowledge, the current study represents
the first comprehensive analysis of c-MYC targeting in a
representative panel of human MB cells expressing differ-
ent levels of c-MYC.
c-MYC siRNA-mediates reduced susceptibility to ionizing radiationFigure 5
c-MYC siRNA-mediates reduced susceptibility to ionizing radiation. Cytotoxicity induced by irradiation in c-MYC 
siRNA and control siRNA-transfected cells was determined by the MTS assay. Values represent the mean percentage of sur-
vival ± SD (n = 3) compared to non-irradiated c-MYC siRNA or control siRNA-transfected cells, respectively. (n = 3; ± SD).
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c-MYC siRNA-mediates reduced susceptibility to cisplatin (A) and etoposide (B) treatmentFigure 6
c-MYC siRNA-mediates reduced susceptibility to cisplatin (A) and etoposide (B) treatment. Cytotoxicity induced 
by etoposide and cisplatin in c-MYC siRNA and in control siRNA-transfected cells was determined by the MTS assay. Values 
represent the mean percentage of survival compared to control cells (n = 3; ± SD). The IC50 values and their 95% confidence 
intervals were calculated from the regression curve and are indicated for each data set.
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BMC Cancer 2009, 9:10 http://www.biomedcentral.com/1471-2407/9/10siRNA-mediated c-MYC down-regulation resulted in an
anti-proliferative effect in all human MB cell lines tested.
Moreover, the ability of c-MYC siRNA-treated MB cells to
form large colonies was significantly reduced. Down-reg-
ulation of c-MYC expression resulted in an activation of
the CDK inhibitor p21 and in a cell cycle arrest at the G0/
G1 phase. These results are supported by findings from
others, demonstrating that c-MYC represses the p21 pro-
moter [44], and showing that c-MYC over-expression in
primary human fibroblasts results in inhibition of p21
transcription [45]. Moreover, the G1-S progression of
eukaryotic cells is in part controlled by c-MYC [2,4,7].
Ectopic expression of c-MYC in quiescent cells promotes
the entry into the S-phase [46,47]. On the other hand,
down-regulation of c-MYC expression by antisense meth-
ods resulted in anti-proliferative effects by preventing S-
phase entry [48,49]. Our investigation shows that c-MYC
inhibition reduces tumor cell growth suggesting that c-
MYC might be an attractive target in MB to inhibit tumor
growth.
siRNA-mediated c-MYC down-regulation resulted in a
down-regulation of hTERT mRNA expression and in a
reduction of telomerase activity in all but D425 human
MB cells. D425 cells are characterized by relatively low
hTERT mRNA expression and TRAP-negativity [40]. How-
ever, the absence of significant correlation between c-MYC
and hTERT expression and the difference seen between
hTERT mRNA and activity inhibition could be attributed
to the presence of several binding sites for other transcrip-
c-MYC siRNA-mediates inhibition of cisplatin- and etoposide-induced apoptosis (A, B) in DAOY MB cells that is associated with reduced processing of caspase-9Figu  7
c-MYC siRNA-mediates inhibition of cisplatin- and etoposide-induced apoptosis (A, B) in DAOY MB cells that 
is associated with reduced processing of caspase-9(C). Minor (A) and moderate (B) induction of apoptosis in DAOY 
V11 cells transfected with siRNAs and exposed to cisplatin and etoposide, respectively. Markedly reduced apoptosis in DAOY 
M2 cells transfected with c-MYC siRNA compared to control siRNA-transfected cells upon cisplatin and etoposide treatment 
(A, B). Reduced processing of caspase-9 in c-MYC siRNA-transfected DAOY M2 cells after cisplatin and etoposide treatment 
as assessed by Western blot analysis (C). Actin was used as a loading control. Values represent the mean absorbance of cyto-
plasmatic histone-associated DNA fragments (representative of two independent experiments, (n = 3; ± SD)).
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BMC Cancer 2009, 9:10 http://www.biomedcentral.com/1471-2407/9/10tion factors – than c-MYC – on hTERT gene promoter and
to the fact that expression of hTERT mRNA is not the only
regulator of telomerase activity [50-52]. Alternative splic-
ing [53], posttranscriptional modification [54,55], sub-
cellular hTERT localization [56] and the presence of
enzyme inhibitors may alter telomerase activity. Moreo-
ver, it has been suggested that a threshold level of hTERT
protein is required in order for telomerase to become
active, therefore low levels of hTERT mRNA may not indi-
cate active telomerase [57]. In this respect, hTERT expres-
sion has not been found to correlate with telomerase
activity in colorectal tumors [58]. Furthermore, hTERT
mRNA expression has been detected in lymphocytes
regardless of telomerase activity [59] and in some normal
telomerase negative tissues such as human brain, prostate
liver and ovary [60]. Telomerase impairment can lead to
the induction of apoptosis through a mechanism that
relies on the inhibition of telomerase catalytic activity and
on the consequent telomere shortening [61,62]. However,
depending on the telomere length, this mechanism is
rather slow. Several generations and a long lag time may
be required before telomeres shorten below a critical
length [62-64]. Holt et al. have showed that cells with
elongated telomeres are more resistant to induction of
apoptosis than their parental counterparts with short tel-
omeres [65]. Our experiments were executed in a short
time window (72 h) due to cell distress upon treatment
with c-MYC siRNA.
DAOY M2 cells engineered to stably over-express c-MYC
show higher basal apoptotic activity compared with
DAOY wt and DAOY V11 cells, and are characterized by
enhanced apoptosis rate in vivo [24]. D425 and D341 MB
cells (both with c-MYC gene amplification and high c-
MYC expression) also show a higher basal apoptotic rate
when compared with DAOY wt cells. Moreover, c-MYC
inhibition resulted in a significant decrease in the apop-
totic rate which was most pronounced in MB cells with
high c-MYC expression. It has been shown that c-MYC can
drive cells to undergo apoptosis [7-9]. However, this
might not be the case for all cell lines. In UW-228 human
MB cells, down-regulation of c-MYC by an antisense
approach resulted not only in an inhibition of cell growth
but also in an increase of apoptosis as determined by
FACS analysis [66].
We then analyzed whether c-MYC down-regulation alters
sensitivity to IR and chemotherapeutic agents and found
a decrease in the sensitivity to IR, cisplatin, and etoposide.
This effect was most prominent in cells expressing high c-
MYC levels. The differences of cytotoxic effect of cisplatin
and etoposide on siRNA-transfected MB cells may be due
to the different mode of action that the two drugs exert.
The cytotoxicity of cisplatin is mediated by its interaction
with DNA to form DNA adducts, which activate several
signal transduction pathways and terminate in the activa-
tion of apoptosis [67], whereas etoposide belongs to the
class of topoisomerase II poison with the ability to stabi-
lize complex between DNA topoisomerase II and DNA
that results in a high level of DNA damage [43]. By
addressing the question of whether c-MYC alters the
response of cells to radio- and chemotherapy, results have
been conflicting [68-74]. Our results are in agreement
with studies demonstrating that c-MYC sensitize a variety
of cells to different cytotoxic treatments [68-70], and that
absence of c-MYC expression might confer resistance to
anti-cancer agents [71]. However, this effect of c-MYC also
seems to be cell type-specific. In human melanoma cells,
a decrease in c-MYC expression has been reported to
enhance the effect of IR [72] and cisplatin treatment
[73,74].
Cancer chemotherapies induce apoptosis [42]. Changes
that decrease the ability to activate the apoptotic machin-
ery might affect the sensitivity of cells to a range of chem-
otherapeutic agents. In order to evaluate whether c-MYC
down-regulation affects the susceptibility to apoptosis, we
investigated the apoptotic response of siRNAs-transfected
DAOY M2 cells following cisplatin and etoposide treat-
ment. This cell line was used, because c-MYC inhibition
caused significant reduction of chemo-sensitivity to cispl-
atin and etoposide. This analysis revealed that down-reg-
ulation of c-MYC attenuated drugs-induced apoptosis that
was associated with a reduced caspase-9 processing. These
results are consistent with findings from other groups
showing that c-MYC inhibition mediates resistance to
chemotherapy-induced apoptosis by preventing activa-
tion of caspase-mediated pathways [68,69,71].
Conclusion
Taken together, our data show for the first time that target-
ing c-MYC in human MB cells decreases cell growth,
induces cell cycle arrest and reduces telomerase activity.
However, c-MYC down-regulation also causes decreased
apoptosis and resistance towards IR, cisplatin, and etopo-
side. Following in vivo validation, targeting c-MYC might
represent a promising strategy to reduce tumor growth in
pretreated MB patients whose tumors have ceased to
respond to chemotherapy. Our data also indicate that tar-
geting c-MYC might not be used concomitantly with
chemotherapy or radiotherapy in MB because of the risk
of reducing the effectiveness of these therapies.
Emerging evidence indicates that the different precursor
cell populations that form the cerebellum and the cell sig-
naling pathways that regulate its development likely rep-
resent distinct compartments from which the variable
subtypes of MB arise [75,76]. It remains to be tested
whether down-regulation of c-MYC has MB subtype spe-
cific effects or is rather MB subtype independent.Page 12 of 14
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